文献速递肾癌与肾肿瘤

PARP1作为预测PBRM1突变透明细胞肾细胞癌患者PD-L1阻断应答的生物标志物

The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2021-10-06

本研究利用311例接受PD-1阻断前瞻性临床试验患者的肿瘤RNA测序数据,探讨PARP1在透明细胞肾细胞癌中的意义。在纳武利尤单抗治疗患者中,PARP1低表达组总生存显著更高,PARP1状态与总生存显著相关;在依维莫司治疗患者中无显著差异。在PBRM1突变亚组中,PARP1低表达且PBRM1突变患者无进展生存和总生存显著更长,PARP1状态与纳武利尤单抗治疗患者的无进展生存和总生存显著相关。

要点

  • PARP1低表达与纳武利尤单抗治疗患者总生存改善显著相关。
  • PARP1状态在依维莫司治疗患者中与生存无显著关联。
  • PBRM1突变且PARP1低表达患者接受纳武利尤单抗后生存显著更优。

核心结论

  • PARP1可作为预测PBRM1突变透明细胞肾细胞癌患者免疫检查点抑制剂治疗应答的生物标志物。

研究设计与样本

  • 利用311例来自PD-1阻断前瞻性临床试验患者的肿瘤RNA测序数据进行分析。
  • 纳武利尤单抗治疗组181例,依维莫司治疗组130例。

主要发现

  • 纳武利尤单抗组中PARP1低表达组总生存显著高于高表达组(p=0.006),PARP1状态与总生存显著相关(HR 1.7;p=0.007)。
  • 依维莫司组中PARP1状态对无进展生存(p=0.9)和总生存(p=0.38)无显著差异。
  • PBRM1突变亚组中,PARP1低表达且PBRM1突变组无进展生存(p=0.016)和总生存(p=0.004)显著更长。
  • PBRM1突变患者接受纳武利尤单抗时,PARP1状态与无进展生存(HR 2.6;p=0.007)和总生存(HR 3.5;p=0.016)显著相关。

关键数值与推荐

  • PARP1低表达且PBRM1突变患者接受纳武利尤单抗后无进展生存和总生存显著优于其他组。
  • PARP1状态与纳武利尤单抗治疗患者的无进展生存和总生存显著相关。

临床怎么用

  • 对于PBRM1突变的透明细胞肾细胞癌患者,可考虑检测PARP1表达以预测PD-1阻断治疗应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) have become key agents in the management of clear cell renal cell carcinoma (ccRCC), but their benefits are limited and responders remain unidentified. We investigated the significance of PARP1 in ccRCC using RNA sequencing data for 311 tumors from patients enrolled in prospective clinical trials of PD-1 blockade. Among patients treated with nivolumab (n = 181), overall survival (OS) was significantly higher in the PARP1-low group than in the PARP1-high group (p = 0.006), and PARP1 status was significantly associated with OS (hazard ratio [HR] 1.7; p = 0.007). By contrast, for patients treated with everolimus (n = 130) there was no significant difference by PARP1 status for progression-free survival (PFS; p = 0.9) or OS (p = 0.38). In subgroup analysis for PBRM1-mutated ccRCC, PFS (p = 0.016) and OS (p = 0.004) were significantly longer in the group with PARP1-low status and PBRM1 mutation in comparison to the other groups. In addition, PARP1 status was significantly associated with PFS (HR 2.6; p = 0.007) and OS (HR 3.5; p = 0.016) among patients with PBRM1-mutated ccRCC treated with nivolumab. Our study suggests that PARP1 can be used as a biomarker for predicting response to ICI treatment for patients with PBRM1-mutated ccRCC. PATIENT SUMMARY: Immune checkpoint inhibitors (ICIs) are key agents in the treatment of multiple cancers. We found that expression of the PARP1 protein was associated with survival after ICI treatment and with the response to ICI treatment in patients with clear cell kidney cancer who have a mutation of the PBRM1 gene.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Hagiwara M, Fushimi A, Matsumoto K, et al. The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2021. PMID: 34627641. doi:10.1016/j.eururo.2021.09.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。